Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

August 22-23, 2014
Dana Point, CA


Continuing Medical Education
Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 9 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend
This educational activity is specifically designed for hematologists, medical oncologists, and other healthcare professionals (physicians, clinicians, physicians-in-training, oncology nurses, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with myelodysplastic syndromes and myeloproliferative diseases.

Upon successful completion of this educational activity, participants will be able to:

  • Describe underlying molecular and genetic events involved in MPNs and MDS and how these events could be utilized within the clinic
  • Evaluate the role of current therapies for the treatment of MDS
  • Summarize current data on newly approved and late-stage investigational therapies for MDS
  • Discuss current therapy options and emerging treatment strategies for polycythemia vera and essential thrombocythemia
  • Interpret ongoing and finalized clinical trials pertaining to the utilization of JAK inhibitors for the treatment of myelofibrosis and their incorporation into current therapeutic regimens
  • Define diagnostic markers for the prognosis of myelofibrosis
  • Explain the latest implications for stem cell transplantation in managing MDS and MF